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Background: Transcriptome analysis has been used in autism spectrum disorder (ASD) to unravel common
pathogenic pathways based on the assumption that distinct rare genetic variants or epigenetic modifications affect
common biological pathways. To unravel recurrent ASD-related neuropathological mechanisms, we took advantage
of the En2−/− mouse model and performed transcriptome profiling on cerebellar and hippocampal adult tissues.
Methods: Cerebellar and hippocampal tissue samples from three En2−/− and wild type (WT) littermate mice were
assessed for differential gene expression using microarray hybridization followed by RankProd analysis. To identify
functional categories overrepresented in the differentially expressed genes, we used integrated gene-network
analysis, gene ontology enrichment and mouse phenotype ontology analysis. Furthermore, we performed direct
enrichment analysis of ASD-associated genes from the SFARI repository in our differentially expressed genes.
Results: Given the limited number of animals used in the study, we used permissive criteria and identified 842
differentially expressed genes in En2−/− cerebellum and 862 in the En2−/− hippocampus. Our functional analysis
revealed that the molecular signature of En2−/− cerebellum and hippocampus shares convergent pathological
pathways with ASD, including abnormal synaptic transmission, altered developmental processes and increased
immune response. Furthermore, when directly compared to the repository of the SFARI database, our differentially
expressed genes in the hippocampus showed enrichment of ASD-associated genes significantly higher than
previously reported. qPCR was performed for representative genes to confirm relative transcript levels compared to
those detected in microarrays.
Conclusions: Despite the limited number of animals used in the study, our bioinformatic analysis indicates the
En2−/− mouse is a valuable tool for investigating molecular alterations related to ASD.
Keywords: En2, Neurodevelopmental disorders, Mouse models, Immune response, Synaptic function, Scn1a, Grm5, Nrxn3Background
Autism spectrum disorder (ASD) defines a complex
group of neurodevelopmental disabilities characterized by a
wide range of impairments in social and communicative
skills, stereotyped behaviors, and restricted mental flexi-
bility [1]. The neurodevelopmental and neuroanatomical
bases of ASD have been confirmed by a number of clinical,* Correspondence: sgado@science.unitn.it
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reproduction in any medium, provided the orneuroimaging and neuropathological studies [1-3]. The
most evident abnormality in ASD consists in an early
(perinatal) brain overgrowth followed by an arrest of growth
during the first year of age [4]. Neuropathological studies
on post-mortem samples from ASD patients also showed a
number of cellular and cytoarchitectural abnormalities at
the level of the cerebral cortex, cerebellum, amygdala and
forebrain limbic structures. Anomalies in the cerebellum
are the most reproducible neuropathological alterations in
ASD patients [3,5].
A large series of evidence clearly indicates that neuro-
pathological features and behavioral deficits of ASD haveLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remains essentially unknown [6,7]. Transcriptome analysis
has also been used to unravel common pathogenic path-
ways based on the assumption that distinct rare genetic
variants or epigenetic modifications affect common bio-
logical pathways dysregulated in ASD [6]. Several studies
have analyzed genome-wide expression profiles of ASD
patients using lymphoblastoid cell lines and blood sam-
ples, supporting upregulation of immune genes and down-
regulation of neurodevelopmental genes as key players in
the pathogenesis of ASD (see [8] for a review). Recently,
gene co-expression network analysis of autistic brain areas
revealed defects in cortical patterning and an enrichment
of differentially expressed genes associated with ASD [9].
The homeobox-containing transcription factor engrailed-2
(En2) is crucially involved in the regionalization, patterning
and neuronal differentiation of the midbrain and hindbrain
[10-15]. Human studies indicated association of two intronic
single-nucleotide polymorphisms (SNPs) in the human
engrailed-2 (EN2) gene with ASD [16,17]. Furthermore,
the ASD associated A-C haplotype markedly affected
EN2 promoter activity when tested with a luciferase re-
porter assay in rat, mouse and human cell lines [18]. A
recent study of the epigenetic evaluation of EN2 in post-
mortem cerebellar samples from autistic patients indi-
cated a persistent upregulation of this homeobox gene
induced by epigenetic abnormalities in histone methyla-
tion patterns that may contribute to Purkinje cell loss in
some individuals with autism [19].
Mice lacking the homeobox domain of En2 (En2hd/hd
mice; [20], referred to as En2−/−) have been proposed as a
model for ASD, due to their complex neuroanatomical
and behavioral phenotype. En2−/− mice display cerebellar
hypoplasia, including a reduced number of Purkinje cells,
and a defect in the antero-posterior pattern of cerebellar
foliation [20-23]. The behavior of En2−/− mice is also rem-
iniscent of some features of ASD individuals. Deficits in
social behaviors were detected in En2−/− mice, including
decreased play and reduced social interactions; locomotor
impairment, as well as defective spatial learning and mem-
ory, was also reported in these mice [24-26]. Furthermore,
we reported dysfunctions in GABAergic interneurons in
adult En2−/− mice and demonstrated engrailed protein ex-
pression in specific subpopulations of adult hippocampal
and cortical interneurons [27].
To unravel recurrent ASD-related neuropathological
mechanisms, we took advantage of the En2−/− mouse
model and performed genome-wide expression profiling
on cerebellar and hippocampal adult tissues. Our tran-
scriptome analysis of the cerebellum and hippocampus
of En2−/− mice suggests convergent pathological pathways
with ASD, including abnormal synaptic transmission
and increased immune response. Furthermore, we provide




Experiments were conducted in conformity with the
European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the Italian
Ministry of Health and Ethics Committee of the University
of Trento. Animals were housed in a 12 hr light/dark cycle
with food and water available ad libitum. All surgery was
performed under chloral hydrate anesthesia, and all efforts
were made to minimize suffering. The generation of En2−/−
mice was previously described [20]. The original En2mutants
(mixed 129Sv x C57BL/6 and outbred genetic background)
were crossed at least five times into a C57BL/6 background.
Heterozygous matings (En2+/− x En2+/−) were used to gener-
ate the En2+/+ (wild type, WT) and En2−/− littermates used
in this study. PCR genotyping was performed according to
the protocol available at the Jackson Laboratory website
(www.jax.org; mouse strain En2tm1Alj). WT and En2−/−
age-matched adult (3 to 5 months old; weight = 25 to 35 g)
littermates mice of both sexes were used.
Microarrays
RNAs from dissected hippocampi and cerebella from three
adult mice for each genotype were purified using standard
column purification according to the manufacturer’s proto-
col (RNAeasy Mini Kit, Qiagen, USA). RNA quality was
analyzed by microfluidic gel electrophoresis on RNA 6000
NanoChips using the Agilent 2100 Bioanalyzer. Only RNA
with a high (>9) RNA integrity number was selected and
used for subsequent retro-transcription, labeling and array
hybridization according to Agilent protocols. Mouse gene
expression arrays (Agilent 4X44K slides) were hybridized
and scanned with the Agilent microarray station.
Bioinformatics
Intensity values were processed with Agi4x44PreProcess
(http://bioconductor.org/packages/2.12/bioc/html/Agi4x44
PreProcess.html) using default parameters to remove low-
quality probes. Signals were then normalized by means of
the quantile normalization method. To evaluate differential
expression, we used RankProd (http://www.bioconductor.
org/packages/2.11/bioc/html/RankProd.html) [28]. RankProd
utilizes the Rank Product (RP) non-parametric method [29]
to identify up- or downregulated genes. The RP is equivalent
to calculating the geometric mean rank with a statistical
method (average rank) that is slightly more sensitive to
outlier data and puts a higher premium on consistency
between the ranks in various lists. To assess for functional
categories overrepresented in the differentially expressed
genes, we used DAVID (http://david.abcc.ncifcrf.gov) and
Ingenuity Pathway Analysis (Ingenuity Systems, Inc., USA).
Figure 1 Venn diagram of differentially expressed genes in
En2−/− adult cerebellum and hippocampus. A total of 842 and
862 differentially expressed genes were identified in the adult
cerebellum (CB, blue) and hippocampus (Hippo, red) of En2−/−
mice, respectively. Among these, 238 show differential expression
in both tissues.
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we used, as background for our functional analyses, a list of
tissue specific ‘expressed genes’ for both the cerebellum
and the hippocampus. Our ‘expressed genes’ lists were ob-
tained by filtering the genes by the normalized expression
values and excluding the ones with the lowest expression
levels (<10th percentile), and include 13,652 genes for the
cerebellum and 13,141 for the hippocampus. The hypergeo-
metric test and the Student’s t-test were computed with R
(http://www.r-project.org).
Quantitative PCR
Total RNAs were extracted by Trizol™ reagent (Invitrogen
Life Technologies, USA) from dissected hippocampi and
cerebella from four WTand four En2−/− adult mice. RNAs
were DNAse-treated and purified with RNeasy Mini
Kit (Qiagen, USA). cDNA was synthesized from pooled
RNAs (2 μg) using the SuperScript™ VILO™ (Invitrogen
Life Technologies, USA) according to the manufacturer’s
instructions. Individual PCR reactions were conducted in
a volume of 20 μl using the KAPA FAST SYBR qPCR kit
(KAPABiosystems, USA) according to manufacturer’s
instructions. Mouse mitochondrial ribosomal protein
L41 (Mrpl41) was used as a standard for quantification
as previously shown [30]. Primers (MWG, Germany)
were designed on different exons to avoid amplification of
genomic DNA. A list of primer sequences is reported in
Additional file 1. Each PCR cycle consisted of denaturation
for 10 s at 94°C, annealing for 20 s at 60°C and extension
for 30 s at 72°C. The fluorescence intensity of SYBR green I
was read and acquired at 72°C after completion of the ex-
tension step of each cycle. PCR conditions for individual
primer sets were optimized by varying template cDNA and
primer concentration in order to obtain a single PCR prod-
uct and amplification efficiency >90%. Relative expression
values were calculated using the Pfaffl method [31].
Results
Differential gene expression in cerebellum and
hippocampus of En2−/− mice
The cerebellum of En2−/− mice shows Purkinje cell loss
and structural abnormalities resembling the neuropatho-
logical features observed in ASD patients [20,21,23]. To
identify genes and pathways altered in En2−/− mice, we ini-
tially performed transcriptome profiling of the whole cere-
bellar tissue. En2−/− and WT cerebella from adult mice
were assessed for differential gene expression by microarray
and bioinformatical analysis (see Methods). We found 842
differentially expressed genes in the cerebellum of En2−/−
mice compared to their control littermates. Among these,
407 and 435 were up- and downregulated, respectively.
Alterations in limbic structures have also been shown in
the temporal lobes of autistic patients. The main abnormal-
ities were shown in the superior temporal sulcus and theventral-basal temporal region, both of which are involved
in decoding social stimuli and therefore are associated with
the social deficits [32-34]. Most importantly, we previously
showed anatomical defects in the En2−/− hippocampus that
might contribute to the behavioral deficits displayed by
these mutants [27]. We therefore combined the cerebellar
gene expression profile to that of the hippocampus.
We found 862 differentially expressed genes in the hippo-
campus, among those 378 were upregulated and 484 were
downregulated in En2−/− mice compared to their littermate
controls. Additional file 2 shows the entire list of genes
differentially expressed in the cerebellum and hippocampus
of En2−/− mice with the differential expression P value and
the percentage of false prediction (pfp) value calculated by
RankProd. Given the profound structural and cytoarchitec-
tural phenotype of the En2−/− cerebellum and the variability
of the phenotype among individuals, we chose to be more
permissive and include genes with smaller differential
expression fold changes applying a moderate cutoff to the
uncorrected P value [see Additional file 2]. Differentially
expressed genes, which are common in the hippocampus
and the cerebellum, are summarized in Figure 1 and listed
in Additional file 3. Remarkably, En2 was not among the
differentially expressed genes. The microarray probe for
En2 (A_51_P397876) was designed on the 3′ untranslated
region of the gene that is not deleted in the En2−/− locus
[20]. Our data confirm the previous reports indicating the
presence of a residual transcript from the En2−/− locus [20].
Furthermore, real-time quantitative PCR (qPCR) ana-
lysis of En2 expression using homeobox specific primers
revealed no expression of the full-length gene in En2−/−
mice [see Additional file 4].
Functional analysis
To explore the biological processes most relevant to the
phenotype of the En2−/− mice, the differentially expressed
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lysis using the curated Ingenuity Pathway Analysis (IPA)
database and the Database for Annotation, Visualization
and Integrated Discovery (DAVID). Additional file 5 shows
the most significantly enriched disease and cellular function
categories obtained with IPA and gene ontology analysis.
Functional categories included increased seizure and
decreased neurotransmission release in the hippocampus,
and decreased cancer-related diseases and development
of lymphocytes as cellular function in the cerebellum.
To identify statistically significant over-representation of
key neurobiological processes, functional annotation ana-
lysis was performed with DAVID using a tissue specific list
of ‘expressed genes’ as background (see Methods). To ver-
ify the tissue-expression pattern of the samples, we first
classified the differentially expressed genes based on their
tissue expression (P <0.05, calculated using Benjamini
multiple testing correction). We only found significant
tissue expression terms for En2−/− hippocampus show-
ing significant enrichment in expression of genes related
to ‘brain cortex’, ‘brain’, ‘hypothalamus’, ‘eye’ and ‘hippocam-
pus’ [see Additional file 6]. We then analyzed the functional
annotation using gene sets from the gene ontology (GO)
public databases and our ‘expressed genes’ list as back-
ground. Figure 2 shows all GO terms enriched in the
differentially expressed genes of En2−/− cerebellum with
the gene counts and the relative P value (P <0.05, calculated
using Benjamini multiple testing correction). Among
the most represented functional categories were several
terms related to the major histocompatibility complex
(MHC)-mediated immunity and immune response. The
GO terms related to the En2−/− hippocampus are shown
in Figure 3 with the gene counts and the relative P value
(P <0.05, calculated using Benjamini multiple testing
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Figure 2 Overrepresented gene ontology categories for differentially
expressed genes (n = 842) were analyzed for enrichment in gene ontology
0.05. Categories are arranged from most significant and downwards (gray l
of the horizontal bars (gene counts). To highlight distinct ontological categ
details are also reported in Additional file 5.cellular components synapse, synaptic vesicle and neuronal
projection. Within the biological processes, the most
represented terms were ‘neuronal activities’ and ‘calcium
mediated signal’. Interestingly, the keyword ‘phospho-
protein’ was significantly enriched, suggesting a generic
alteration in the protein phosphorylation state in the
En2−/− hippocampus.
To assess the functional consequences of En2 ablation,
we analyzed enrichment of the differentially expressed
genes based on the mouse phenotype from the Mammalian
Phenotype Ontology (MPO) project [35], using ToppGene
[36]. In the En2−/− cerebellum the only significantly
enriched mouse phenotype was ‘loss of dopaminergic
neurons’, a term associated with the cerebellar phenotype
by the role of En2 in midbrain/hindbrain development and
dopaminergic neuron survival [37,38]. For the hippocam-
pus we found significant enrichment for terms related to
seizure and altered synaptic transmission (Figure 4). These
data are in accordance with our previously described in-
crease in seizure susceptibility and decrease in GABAergic
neuron subpopulations in En2−/− mice [27,30].
Remarkably, when analyzed specifically for ASD-
associated genes, the differentially expressed genes showed
significant over-representation of known ASD susceptibil-
ity genes when compared directly to the repository of the
Simons Foundation and Autism Research Initiative (SFARI)
database (gene.sfari.org). Since the SFARI database com-
prises genes related to neurodevelopmental disorders, there-
fore expressed in the brain, we filtered the SFARI database
gene list with our list of ‘expressed genes’ in the cerebellum
and in the hippocampus (see Methods for details). We used
these SFARI gene lists to calculate enrichment with our
differentially expressed genes. Table 1 shows the list of
the ASD-associated differentially expressed genes for the
cerebellum and the hippocampus. To compute significantP-value
gene counts
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Figure 3 Overrepresented gene ontology categories for differentially expressed genes in the En2−/− adult hippocampus. Differentially
expressed genes (n = 862) were analyzed for enrichment in gene ontology categories using public databases with a Benjamini corrected P value
cutoff of 0.05. Further details regarding the figure and inset are described in the legend to Figure 2. Data details are also reported in Additional file 5.
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the SFARI genes, we employed the hypergeometric test. The
statistical analysis indicated significant enrichment only for
the hippocampus (P <0.05), whereas no significant enrich-
ment was observed for the cerebellum.
To compare our findings with the three major genome-
wide expression studies on ASD brain tissue [9,39,40], we
matched the publicly available differentially expressed
genes with the same ASD-related gene lists that we
used for our analysis. To increase accuracy, we computed,
for each study, the hypergeometric test and obtained an
enrichment P value that we used for direct comparison.
Table 2 summarizes the results of the enrichment analyses,0
abnormal excitatory postsynaptic currents
seizures
abnormal synaptic transmission
abnormal CNS synaptic transmission
0.00 0.01
10
Figure 4 Mouse phenotype categories associated with differentially e
genes in En2−/− hippocampus were analyzed for enrichment in mouse phe
Categories are arranged from most significant and downwards (gray line); n
horizontal bars (gene counts).separated in tissue-specific groups, and the comparison
between the studies. For Voineagu et al. [9] we re-analyzed
the cerebellum data using the GEO2R tool with default pa-
rameters and used these results to evaluate the correspond-
ence with our study. The results for cerebellum show a
significant enrichment with ASD-associated genes only for
the Voineagu et al. study (4.75% enrichment, P = 0.0343).
Our study, however, was the only one to display significant
enrichment of ASD-related genes (4.24% enrichment,
p = 0.0265) in the limbic regions.
To validate microarray findings with qPCR analysis, we
selected eight and eighteen representative genes from the
cerebellum and the hippocampus differentially expressed2 50 0
0.0 .0
30 40
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Table 1 Enrichment of autism spectrum disorder (ASD)-related genes in En2−/− cerebellum and hippocampus
differentially expressed genes
(a) Cerebellum
Gene Symbol Gene Name P value Fold change
Ada adenosine deaminase 3.50E-03 1.705
Ahi1 Abelson helper integration site 1 4.70E-03 1.690
Cacna1g calcium channel, voltage-dependent, T type, alpha 1G subunit 8.20E-03 0.670
Cdh10 cadherin 10 4.40E-03 1.662
Eml1 echinoderm microtubule associated protein like 1 2.80E-03 0.581
Erbb4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 9.90E-03 0.653
Glo1 glyoxalase 1 6.00E-03 0.625
Gnas GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus 5.60E-03 1.565
Grm5 glutamate receptor, metabotropic 5 3.70E-03 1.656
Itgb7 integrin beta 7 1.00E-04 0.453
Kdm5c lysine (K)-specific demethylase 5C 8.50E-03 0.660
Kit kit oncogene 3.00E-03 0.591
Nrp2 neuropilin 2 0.00 2.503
Nrxn3 neurexin III 1.80E-03 1.843
Park2 Parkinson disease (autosomal recessive, juvenile) 2, parkin 5.20E-03 1.723
Pinx1 PIN2/TERF1 interacting, telomerase inhibitor 1 1.00E-03 1.871
Plcb1 phospholipase C, beta 1 3.60E-03 1.677
Rb1cc1 RB1-inducible coiled-coil 1 6.90E-03 1.635
Rpp25 ribonuclease P 25 subunit (human) 8.00E-03 0.619
Stk39 serine/threonine kinase 39, STE20/SPS1 homolog (yeast) 9.40E-03 1.548
Th tyrosine hydroxylase 7.90E-03 1.564
(b) Hippocampus
Gene Symbol Gene Name P value Fold change
Aff4 AF4/FMR2 family, member 4 1.30E-03 4.490
Atp2b2 ATPase, Ca++ transporting, plasma membrane 2 2.80E-03 0.544
Baiap2 brain-specific angiogenesis inhibitor 1-associated protein 2 8.00E-04 0.478
Camta1 calmodulin binding transcription activator 1 4.40E-03 0.561
Dab1 disabled homolog 1 (Drosophila) 4.10E-03 0.552
Dctn5 dynactin 5 4.10E-03 1.733
Dlg4 discs, large homolog 4 (Drosophila) 0.00 0.346
Egr2 early growth response 2 7.00E-04 2.099
Eif4ebp2 eukaryotic translation initiation factor 4E binding protein 2 3.90E-03 0.551
Ep400 E1A binding protein p400 2.00E-04 2.361
Foxp1 forkhead box P1 3.00E-04 0.425
Gabra4 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 4 4.00E-04 2.151
Gnas GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus 3.90E-03 0.555
Gsk3b glycogen synthase kinase 3 beta 3.50E-03 0.541
Gtf2i general transcription factor II I 3.80E-03 0.552
Kit kit oncogene 2.00E-04 0.417
Klc2 kinesin light chain 2 4.80E-03 0.565
Lrrc1 leucine rich repeat containing 1 4.20E-03 1.742
Nrcam neuron-glia-CAM-related cell adhesion molecule 3.10E-03 1.777
Ntng1 netrin G1 1.90E-03 1.842
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Table 1 Enrichment of autism spectrum disorder (ASD)-related genes in En2−/− cerebellum and hippocampus
differentially expressed genes (Continued)
Ntrk3 neurotrophic tyrosine kinase, receptor, type 3 1.00E-04 0.426
Park2 Parkinson disease (autosomal recessive, juvenile) 2, parkin 1.00E-04 2.402
Plcb1 phospholipase C, beta 1 8.00E-04 0.487
Prkcb protein kinase C, beta 8.00E-04 0.490
Rpp25 ribonuclease P 25 subunit (human) 1.10E-03 0.487
Sbf1 SET binding factor 1 4.40E-03 0.562
Scn1a sodium channel, voltage-gated, type I, alpha 1.00E-04 0.410
Scn8a sodium channel, voltage-gated, type VIII, alpha 1.00E-04 0.414
Syn1 synapsin I 5.00E-04 0.469
Syne1 synaptic nuclear envelope 1 4.80E-03 0.562
Thra thyroid hormone receptor alpha 1.00E-04 0.419
Ube2h ubiquitin-conjugating enzyme E2H 4.00E-03 0.559
Ubl7 ubiquitin-like 7 (bone marrow stromal cell-derived) 3.70E-03 0.557
ASD-related genes enriched in the En2−/− (a) cerebellum and (b) hippocampus with their differential expression P value and fold change.
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ferential expression values in microarray experiments ran-
ging between 0.41 fold decrease to 2.5 fold increase. With
qPCR, five of the eight selected genes showed statistically
significant differential expression in the En2−/− cerebellum
[glutamate receptor, metabotropic 5 (Grm5) P = 0.031;
neurexin III (Nrxn3) P = 0.032; neuropilin 2 (Nrp2) P =
0.009; v-erb-a erythroblastic leukemia viral oncogeneTable 2 Correlation of Simons Foundation and Autism Resear
transcriptome studies in Autism Spectrum Disorder (ASD) bra
Cerebellum # SFARI
genes
% enrichment P value
This study (3 En2−/−, 3 WT) 21 2.79% 4.98E-01
Voineagu et al. [9]
(11 autism, 10 controls)
16 4.75% 3.43E-02 (*)
Purcell et al. [39]
(9 autism, 9 controls)
1 3.33% 5.85E-01
Limbic regions # SFARI
genes
% enrichment P value
This study (3 En2−/−, 3 WT) 33 4.24% 2.65E-02 (*)
Voineagu et al. [9]
(13 autism, 13 controls)
36 3.70% 1.04E-01
Garbett et al. [40]
(6 autism, 6 controls)
4 3.05% 5.52E-01
Percentage of enrichment calculated on SFARI ASD-associated genes compared to
Voineagu et al. [9] calculated using GEO2R analysis. Genes present in at least two o
hypergeometric test, (*) P <0.05.homolog 4 (Erbb4) P = 0.003; calcium channel, voltage-
dependent, T type, alpha 1G subunit (Cacna1g) P = 0.003]
(Figure 5a). Fifteen genes of the eighteen selected were
instead significantly changed in the En2−/− hippocam-
pus [netrin G1 (Ntng1) P = 0.008; Parkinson disease
(autosomal recessive, juvenile) 2, parkin, (Park2) P = 0.004;
gamma-aminobutyric acid (GABA) A receptor, subunit
alpha 4 (Gabra4) P = 0.007; early growth response 2 (Egr2)ch Initiative (SFARI) database genes with published
in and our study
Gene names
Ada, Ahi1, Cacna1g, Cdh10, Eml1, Erbb4, Glo1, Gnas, Grm5, Itgb7,
Kdm5c, Kit, Nrp2, Nrxn3, Park2, Pinx1, Plcb1, Rb1cc1, Rpp25, Stk39, Th
AHI1, ANK3, CACNA1G, CBS, EN2, EPHB6, FAT1, FOXP1,GAP43, GRIN2A,
HSD11B1, NLGN3, NTNG1, RAB11FIP5, SLC30A5, UBE3A
CNR1
Gene names
Aff4, Atp2b2, Baiap2, Camta1, Dab1, Dctn5, Dlg4, Egr2, Eif4ebp2,
Ep400, Foxp1, Gabra4, Gnas, Gsk3b, Gtf2i, Kit, Klc2, Lrrc1, Nrcam,
Ntng1, Ntrk3, Park2, Plcb1, Prkcb, Rpp25, Sbf1, Scn1a, Scn8a, Syn1,
Syne1, Thra, Ube2h, Ubl7
AHI1, APBA2, ATP2B2, ATRNL1, AUTS2, BCL2, BTAF1, CADM1, CD99L2,
DNM1L, DPP10, EIF4EBP2, FAT1, GRIN2A, ICA1, MAOA, MSN, NTRK3,
PCDH9, PPFIA1, PRKCB, PTCHD1, RAB11FIP5, RGS7, RPP25, SLC16A3,
SLC25A12, SLC9A9, STXBP1, SYT17, TOMM20, TSC2, TUBGCP5, UBE2H,
UBR5, UPF3B
AHI1, MSN, SDC2, SLC9A9
the number of differentially expressed genes. Differentially expressed genes in































































































Figure 5 Quantitative PCR validation of differentially expressed genes. A selected number of differentially expressed genes in the En2−/−
cerebellum (a) and hippocampus (b) were validated by qPCR. Relative mRNA expression level (fold expression) as obtained by qPCR performed
on whole cerebellum or hippocampus extracts of adult wild type (WT) and En2−/− mice. Correlation of fold expression from qPCR (light color bars) and
microarray (dark color bars) results was calculated using Pearson’s Correlation. Except for Egr2, qPCR results for all the evaluated genes showed
significant correlation with microarray results (R = 0.84; P <0.05). Values are expressed as each gene/L41 comparative quantitation ratios normalized on
the expression of WT (mean ± s.e.m of three replicates from pools of four animals per genotype; P <0.01, Student’s t-test, WT versus En2−/−.
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(Scn1a) P = 0.001; neurotrophic tyrosine kinase, receptor,
type 3 (Ntrk3) P = 0.0003; phospholipase C, beta 1 (Plcb1)
P = 0.0001; cortactin (Cttn) P = 0.0005; synapsin I (Syn1)
P = 0.007; fragile X mental retardation, autosomal homolog
2 (Fxr2) P = 0.0004; protein kinase C, beta (Prkcb) P = 0.001;
gamma-aminobutyric acid (GABA) B receptor, 1, (Gabbr1)
P = 0.03; neuroligin 2 (Nlgn2) P = 0.001; glycogen synthase
kinase 3 beta (Gsk3b) P= 0.003; GNAS (guanine nucleotide
binding protein, alpha stimulating) complex locus (Gnas)
P = 0.01] (Figure 5b). Except for Egr2, in all tested genes
the expression differences reported by qPCR correlated
with the microarray data (Pearson r = 0.84, P < 0.00005).
Discussion
To date, more than 500 autism-associated genes have been
identified (SFARI Gene; gene.sfari.org; updated mar/2013);
yet the etiology of ASD remains essentially unknown [6,7].
The significance of animal models in ASD research has
been widely recognized as important for unraveling the
molecular, cellular, anatomical, electrophysiological and
behavioral consequences of gene dysfunction in ASD. Here,
we present a transcriptome analysis in a mouse model
of ASD of two brain areas, the cerebellum and the
hippocampus, areas that are profoundly affected in ASD
patients. Despite the small number of samples used for
the microarray analysis and the sample gender heterogen-
eity, the low genetic variance among individuals allowed a
reasonable statistical power for our bioinformatic analysis.
Our study revealed that the molecular signature of these
two brain regions shares convergent pathological pathwayswith ASD, including abnormal synaptic transmission
and increased immune response. Furthermore, when
directly compared to the repository of the SFARI database
(gene.sfari.org), our differentially expressed genes in the
hippocampus show an enrichment of ASD-associated genes
significantly higher than previously reported [41].
Transcriptome analysis has been employed to unravel
common pathways based on the assumption that the
core phenotypes of ASD may be caused by convergent
molecular mechanisms [6]. Several studies have analyzed
genome-wide expression profiles of lymphoblastoid cell
lines and blood samples from ASD patients, pointing to
an upregulation of immune genes as key mechanisms in
the pathogenesis of ASD [8]. Despite the limited source
of brain tissue samples from ASD cases and the technical
restrictions, studies of ASD brain transcriptome are emer-
ging as strategic for uncovering functionally relevant alter-
ations in gene expression. A previous microarray study
found alterations of glutamatergic neurotransmission in
ASD cerebellum [39], and expression profiles from ASD
patient temporal cortices showed upregulation of genes
involved in innate immune response and downregulation
of several neurodevelopmental genes [40]. Moreover, the
transcriptome profiles from three different brain regions
(frontal cortex, temporal cortex and cerebellum) of nine-
teen autism cases and seventeen controls were investigated
recently using classical differential expression analysis and
a network-based approach [9]. These analyses showed up-
regulation of genes involved in immune response and
downregulation of genes involved in synaptic function and
vesicular transport [9]. Our results are in accordance with
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gene-network analysis and mouse phenotypes analysis, we
report significantly enriched functions and pathways that
were previously associated to ASD [42]. In detail, we found
increased immune response and major histocompatibility
complex-related immunity in the En2−/− cerebellum;
decreased and abnormal neurotransmission and increased
seizures in the En2−/− hippocampus [see Additional file 5
for details]. Moreover, by direct comparison with the SFARI
repository of ASD-related genes, we show that the gene ex-
pression changes observed in the En2−/− hippocampus were
significantly enriched in ASD-related genes. Furthermore,
the proportion of ASD-associated genes enrichment in
En2−/− hippocampus was significantly higher than previous
studies (Table 2) when compared with Voineagu et al. [9],
likely the most comprehensive transcriptome study of ASD
post-mortem brain to date. In the case of the cerebellum,
in contrast to Voineagu et al. [9] we did not find significant
enrichment of ASD-associated genes in En2−/− mice. Such
difference could be the result of the complex structural
and cytoarchitectural abnormalities in En2−/− cerebellum
[20,21] and the consequent phenotypical variability, or
could simply reflect differences between mouse and human
phenotypes, as the incidence of cerebellar hypoplasia was
not reported in the diagnostic criteria used in the study [9].
Remarkably, EN2 was among the differentially expressed
genes found in Voineagu et al. [9], confirming our evidence
about the role of En2 in the neuropathology of ASD, and in
anterior brain structures [27].
Among the differentially expressed genes, Grm5, Nrxn3
and Scn1a are of particular interest for ASD. Grm5 encodes
mGluR5, a G-protein coupled receptor for the neuro-
transmitter glutamate [43]. In a recent study, mGluR5
has been shown to participate in the pathogenesis of fragile
X syndrome (FXS) while genetic downregulation of Grm5
was able to compensate for some of the symptoms in a
mouse model of FXS [44]. Furthermore, Grm5 was shown
to be downregulated in hippocampal neurons lacking
Shank3, another ASD-associated gene [45]. These data
support a central role for Grm5 in neurobiological pathways
related to ASD pathogenesis. Our results show an increased
expression of Grm5 in the cerebellum of En2−/− mice, sug-
gesting a role of Grm5 in the cerebellar phenotype of these
mice. The contribution of Grm5 and its interaction with
Fmr1 in the En2−/− hippocampus remains to be established
and could open new perspective of pharmacological and
genetic rescue of the ASD-related phenotype of these mice.
Nrxn3 encodes neuronal adhesion proteins of the
Neurexin (NRXN) family. NRXNs are presynaptic cell
adhesion proteins that form trans-synaptic complexes
with their postsynaptic counterpart neuroligins (NLGNs)
and have important roles in synapse development and
function [46]. Recently, a report of hemizygous and de novo
deletions involving NRXN3 in ASD families providedstrong support for a causative link between the loss of
NRXN3 and the development of ASD [47]. Our results of
an increased expression of Nrxn3 in the cerebellum suggest
alterations in Purkinje cell synaptic formation, where
NRXNs have been shown to participate to the forma-
tion of glutamatergic synapses through interaction with
Cerebellin 1 precursor protein (also downregulated in
the En2−/− cerebellum) and GluR∂2 [48,49].
Scn1a encodes the voltage-gated sodium channel alpha
subunit. De novo null mutations in SCN1A result in severe
myoclonic epilepsy of infancy [50]. SCN1A mutations have
been associated to a number of neurological disorders,
including generalized epilepsy with febrile seizures plus,
Dravet syndrome, borderline myoclonic epilepsy in infancy,
intractable childhood epilepsy with generalized tonic-clonic
seizures, familial hemiplegic migraine, and a number of
cryptogenic focal and generalized epilepsies. Recently,
de novo mutations in SCN1A have been associated with
ASD [51], and a report of a recognized mutation in SCN1A
suggests a wide phenotypic variation of the gene mutations
causing a variety of neurologic disorders, including ASD
[52]. In mice, heterozygous loss-of-function mutation in
Scn1a (Scn1a+/−), reproduces several of the symptoms asso-
ciated to the human mutation, such as thermally induced
and spontaneous seizures, premature death, ataxia and
sleep disorder [53,54]. Scn1a+/− mice show both cognitive
deficits and autistic traits that are caused by impaired
GABAergic neurotransmission and can be rescued by drug
treatment. Scn1a down-regulation in the En2−/− hippo-
campus could contribute to the abnormal excitability and
altered GABAergic neurotransmission shown in these mice
by our previous studies [27,30]. Pharmacological rescue of
the hippocampal phenotype in the En2−/− with GABAergic
drugs is currently under investigation.
Anomalies in the cerebellum are the most reproducible
neuropathological alterations in ASD patients. Several cere-
bellar abnormalities have been observed in mouse models
of both En2 gain- and loss-of-function. Ectopic overexpres-
sion of En2 in Purkinje cells during late embryonic and
postnatal cerebellar development results in reduced cere-
bellar volume and loss of Purkinje cells and other cerebellar
neurons [55,56]. Interestingly, En2 knock-out causes defect-
ive cerebellar patterning, reduced Purkinje cell number and
abnormal dendritic foliation [10,57], indicating that alter-
ations in En2 expression levels during development cause
similar phenotypes. Furthermore, deficits in social behav-
iors as well as defective spatial learning and memory were
also reported in En2−/− mice [24-26]. A recent epigenetic
analysis of EN2 promoter methylation in the cerebellum of
ASD individuals indicated hypermethylation of the pro-
moter region and persistent upregulation of the gene. The
authors report that promoter hypermethylation is normally
associated with a decrease in gene expression and suggest
the possibility of a developmental mechanism intended to
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ment [19]. Taken together, this evidence suggests that an
overall imbalance in EN2 expression may be relevant for
ASD pathogenesis, as it could produce alterations in critical
brain functions. Comparable evidence of a similar dosage
effect has been reported in the case of mutations of other
genes critically involved in gene expression regulation and
maintenance of synaptic and neuronal homeostasis, such
as MECP2 and ARX [58,59]. It remains to be established
whether En2 overexpressing mice display abnormal be-
haviors relevant to autism. Microarray data have been
produced for En2 overexpressing Purkinje cells on a differ-
ent platform; however, the results overlap only marginally
with the herein reported study [60].
Conclusions
Using transcriptome analysis, we identified over 800 genes
differentially expressed in the cerebellum and hippocampus
of En2−/− mice. Despite the small number of samples used
and the relatively small statistical power, our study is the
first to analyze molecular changes occurring in two brain
structures with neuroanatomical alterations relevant to
ASD in a mouse model of this disease. Our bioinformatic
analysis of the molecular signature of En2−/− cerebellum
and hippocampus shows a significant convergence of
neurobiological pathways previously linked to ASD path-
ology in brain samples from ASD patients. Overall, the
present study points to a strong impact of transcriptome
analysis on mouse models for identifying neurobiological
pathways commonly altered when ASD genes are disrupted
in a human patient and in a mouse model alike. Further-
more, together with the frequent association of cerebellar
neuroanatomical alterations to the neuropathology of ASD,
our molecular analysis suggests a contribution also for the
hippocampus, where molecular changes relevant to ASD
may occur also in human patients. This notion is supported
by the consistent enrichment of ASD-related genes in
the En2−/− hippocampus compared to the cerebellum
and to other similar studies performed on ASD patient
tissue samples [41]. Finally, our results confirm the
En2−/− mouse model of ASD as a valuable tool for in-
vestigating neuroanatomical, behavioral, as well as mo-
lecular alterations related to ASD.
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